<DOC>
	<DOCNO>NCT02898012</DOCNO>
	<brief_summary>The optimal treatment glioblastoma multiforme ( GBM ) patient age ≥70 year Karnofsky performance status ( KPS ) &lt; 70 unestablished . This clinical trial evaluate efficacy safety upfront temozolomide ( TMZ ) bevacizumab ( Bev ) patient age ≥70 year KPS &lt; 70 .</brief_summary>
	<brief_title>Temozolomide Plus Bevacizumab Supratentorial Glioblastoma 70 Years Older Patients With Impaired Functional Status</brief_title>
	<detailed_description>Elderly patient age 65 year old account approximately 45 % GBM patient , figure expect rise concurrently age population country . Unfortunately , trial perform set . In elderly patient good functional status ( KPS &gt; 70 ) , radiotherapy ( RT ) prolong overall survival ( OS ) without cause detriment quality life compare palliative care alone . Recently , show TMZ could alternative RT . In elderly patient poor functional status symptom onset ( KPS &lt; 70 ) , RT appear satisfactory option frail population ; however , investigator previously find TMZ alone associate improvement functional status 1/3 case appear increase survival compare supportive care alone , especially methylated MGMT promoter patient . Bevacizumab ( Bev ) antiangiogenic monoclonal antibody target VEGF ( vascular endothelial growth factor ) currently use recurrent GBM , particularly combination alkylating agent . Its effect first line treatment combination TMZ RT controversial . In study , investigator evaluate efficacy safety upfront combination TMZ + Bev initial treatment elderly patient GBM impair functional status ( KPS &lt; 70 ) .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Supratentorial Glioblastoma diagnose biopsy . Patients age ≥ 70 year KPS &gt; 30 &lt; 70 Life expectancy &gt; = 8 week Patients enrol least 14 day stereotactic biopsy 28 day surgical biopsy . CT brain MRI perform within 4 week treatment rule haemorrhage . Included health social security system Medical assessment previous inclusion Informed consent form Previous treatment Surgical resection , RT chemotherapy tumor . Hemoglobin level &lt; 9 g % Absolute neutrophil count &lt; 1500 Platelet count &lt; 100.000 ASAT ALAT level 3 time upper limit normal . Bilirubin level 2 time upper limit normal Creatinin 1.5 time upper limit normal Untreated high blood pressure &gt; 150/100 mmHg Congestive cardiac failure Proteinuria &gt; 1 gr/24h INR &gt; 1.5 upper limit normal Recent symptomatic haemorrhage History abnormal wound heal Gastrointestinal fistula Haemoptysis &gt; grade 2 ( NCICTC ) Intracranial abscess Coagulation disorder Active infection require intravenous antibiotic Vascular disease ( include myocardial infarction , unstable angina , cerebrovascular disease , peripheral arterial aortic disease ) previous 6 month Malignancy diagnose previous 5 year ( except basocellular skin cancer situ cervix cancer ) Allergy dacarbazine , Bevacizumab , Temozolomide excipients , recombinant human monoclonal antibody , ovarian cell Chinese hamster .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>temozolomide</keyword>
	<keyword>bevacizumab</keyword>
</DOC>